A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Trial Profile

A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Iobenguane (Primary)
  • Indications Paraganglioma; Pheochromocytoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Molecular Insight Pharmaceuticals; Progenics Pharmaceuticals
  • Most Recent Events

    • 02 Nov 2017 According to a Progenics Pharmaceuticals media release, results from this trial were presented at the, 5th International Symposium on Pheochromocytoma and Paraganglioma (ISP), the North American Neuroendocrine Tumor Society (NANETS) 2017 Annual Symposium, and the 30th Annual Congress of the European Association of Nuclear Medicine (EANM).
    • 02 Nov 2017 According to a company media release, Progenics Pharmaceuticals has completed the rolling submission of its New Drug Application (NDA) for AZEDRA (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma, which are rare neuroendocrine tumors. The NDA was supported by data from this trial.
    • 16 Oct 2017 Overall tumor response assessment data from this trial will be presented at the 30th Annual Congress of the European Association of Nuclear Medicine (EANM), according to a Progenics Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top